All In Biotech

Drug Trial Radar · NCT05467995

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Jun 2, 2021

Primary completion

Apr 25, 2022

Study completion May 19, 2022

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.

Conditions

  • Ankylosing Spondylitis

Interventions

  • AK111Biological

    AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

  • PlaceboBiological

    Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response at Week 16.Time frame: Week16
  2. Percentage of subjects with treatment-emergent adverse events (TEAEs) during the study.Time frame: Baseline to Week20
  3. Percentage of subjects with treatment-emergent serious adverse events (SAEs) during the study.Time frame: Baseline to Week20

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of Bengbu medical college

    Bengbu, Anhui, China

  • Peking university people's hospital

    Beijing, Beijing Municipality, China

  • Peking University Shougang hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Xuanwu hospital capital medical university

    Beijing, Beijing Municipality, China

  • Guangdong provincial people's hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • The first affiliated hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower hospital

    Nanjing, Jiangsu, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The first Bethune hospital of Jilin university

    Changchun, Jilin, China

  • Second hospital of Shanxi Medical university

    Taiyuan, Shanxi, China

  • The seventh affiliated hospital, Sun Yat-sen university

    Shenzhen, Shenzhen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.